ArriVent BioPharma, Inc. (AVBP)

NASDAQ: AVBP · Real-Time Price · USD

19.95

+0.11 (0.55%)

Oct 6, 2025, 4:00 PM EDT - Market closed

ArriVent BioPharma Employees

ArriVent BioPharma had 52 employees as of December 31, 2024. The number of employees increased by 12 or 30.00% compared to the previous year.

Employees

52

Change (1Y)

12

Growth (1Y)

30.00%

Revenue / Employee

n/a

Profits / Employee

-$2,630,577

Market Cap

809.35M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	52	12	30.00%
Dec 31, 2023	40	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

AVBP News

14 days ago - ArriVent Appoints Brent S. Rice as Chief Commercial Officer - GlobeNewsWire
27 days ago - Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer - GlobeNewsWire
2 months ago - ArriVent BioPharma Reports Second Quarter 2025 Financial Results - GlobeNewsWire
2 months ago - ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 - GlobeNewsWire
3 months ago - Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
3 months ago - ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
3 months ago - ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
3 months ago - ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study - GlobeNewsWire